Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia
Ezetimibe/simvastatin therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Ezetimibe/simvastatin is an effective and generally well tolerated adjunct to dietary therapy for markedly reducing lowdensity lipoprotein cholesterol (LDL-C) levels and improving other lipid parameters across diverse patient populations. Dual treatment with ezetimibe/simvastatin is more effective than monotherapy with an HMG-CoA reductase inhibitor (statin), and the addition of ezetimibe to current statin therapy is more effective than doubling the statin dose.
Acknowledgments and Disclosures
This article was reviewed by: M. Averna, Department of Clinical Medicine and Emerging Diseases, University of Palermo Medical School, Palermo, Italy; W.H. Frishman, Department of Medicine, New York Medical College, Valhalla, NY, USA; S. Saluja, Consultant in Internal Medicine, Saran Ashram, Agra, India.
The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
- 1.National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17. 106 (25): 3143–421.Google Scholar
- 5.Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events: results of the dyslipidemia international study (DYSIS). Wien Klin Wochenschr 2011 Oct; 123(19–20): 611–617.PubMedCrossRefGoogle Scholar
- 14.Vytorin tablets: summary of product characteristics [in Portuguese]. Trofa, Portugal: BIAL-Portela & Co., SA, 2011 Apr 11.Google Scholar
- 15.Goltor tablets: summary of product characteristics [in Italian]. Rome: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., 2011.Google Scholar
- 16.Inegy tablets: UK summary of product characteristics. Hoddesdon; MSD-SP Ltd, 2011 Jul 28.Google Scholar
- 17.Vytorin (ezetimibe/simvastatin) tablets: US prescribing information. North Wales (PA): Merck/Schering-Plough Pharmaceuticals, 2011 Jun.Google Scholar
- 22.Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 Nov. 6 (11): 1758–73.CrossRefGoogle Scholar
- 23.Feldman T, Koren M, Insull Jr W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93 (12): 1481–6.PubMedCrossRefGoogle Scholar
- 24.Masana L, Mata P, Gagné C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebocontrolled, 48-week extension study. Clin Ther 2005 Feb. 27 (2): 174–84.PubMedCrossRefGoogle Scholar
- 25.Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011 Jul. 13 (7): 615–28.Google Scholar
- 27.Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy: the IN-CROSS study. Int J Clin Pract 2009 Apr; 63(4): 547–559.PubMedCrossRefGoogle Scholar
- 37.Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011 Mar. 27 (3): 685–92.PubMedCrossRefGoogle Scholar
- 38.Winkler K, Jacob S, Müller-Schewe T, et al. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis. Epub 2011 Nov 9.Google Scholar
- 40.Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008 Nov. 156 (5): 826–32.PubMedCrossRefGoogle Scholar
- 41.McCormack T, Harvey P, Gaunt R, et al. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010 Jul. 64 (8): 1052–61.PubMedCrossRefGoogle Scholar